Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

BACKGROUND: The administration of second- or third-generation anti-CD19 chimeric antigen receptor (CAR) T cells has remarkably improved the survival of patients with relapsed or refractory B cell malignancies. However, there are limited clinical results from fourth-generation CAR-T cell therapy, and...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Front Immunol
मुख्य लेखकों: Zhou, Xuan, Tu, Sanfang, Wang, Chunsheng, Huang, Rui, Deng, Lan, Song, Chaoyang, Yue, Chunyan, He, Yanjie, Yang, Jilong, Liang, Zhao, Wu, Anqin, Li, Meifang, Zhou, Weijun, Du, Jingwen, Guo, Zhenling, Li, Yongqian, Jiao, Cheng, Liu, Yuchen, Chang, Lung-Ji, Li, Yuhua
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Frontiers Media S.A. 2020
विषय:
Immunology
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7731732/
https://ncbi.nlm.nih.gov/pubmed/33329526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.564099
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन